Protective effect of nebulized heparin in the animal models of smoke inhalation injury: A meta-analysis and systematic review of experimental studies.

The pathophysiological mechanism of abnormal coagulation can result from smoke inhalation injury (SII). Heparin nebulization is a common treatment for lung disorders. This study aimed to use meta-analysis in animal models to examine the effectiveness of atomized heparin on SII. For our online searches, we used the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Chinese BioMedical Literature Database (CBM), and Wanfang Database up to January 2022. Data for SII were retrieved and compared to control animals. The studies' findings were determined by combining standardized mean difference (SMD) analysis with 95% confidence intervals (CIs). The findings showed that as compared to the control group, the heparin-treated group had a lower death rate (relative risk (RR) 0.42; 95% CI 0.22, 0.80; P < 0.05). The meta-analysis demonstrated favorable changes in lung physiology, including PaO2/FiO2 (SMD 1.04; 95% CI 0.65, 1.44; P < 0.001), lung wet-to-dry (W/D) weight ratio (SMD -1.83; 95% CI -2.47, -1.18; P < 0. 001), and pulmonary shunt Qs/Qt (SMD -0.69; 95% CI -1.29, -0.08; P < 0.05) after heparin nebulization for lung injury. The present data indicated that pulmonary artery mean pressure (PAMP) in the heparin therapy group was significantly lowered after 24 and 48 h (hours) of therapy, suggesting that the cardiovascular system could recover following heparin treatment. As a result, heparin nebulization appeared to be more effective against SII and improved cardiopulmonary function compared to the control group.